# Transgenic Core (TGC)

> **NIH NIH P30** · SALK INSTITUTE FOR BIOLOGICAL STUDIES · 2024 · $184,351

## Abstract

PROJECT SUMMARY – TRANSGENIC
The mission of the Transgenic Shared Resource (TGC) is to provide Salk Cancer Center (SCC) members access
to cutting-edge technologies for creating genetically engineered mouse models (GEMMs). GEMMs are critical
tools that enable researchers to model human cancer, to analyze and functionally manipulate specific genes,
and to test potential therapeutic interventions. Established in 1994 with CCSG and Institutional funds, the facility
remains relevant to SCC researchers today. On average, the TGC serves 42% (13/31) of SCC members annually
who are responsible for 74% of all TGC services based on recharges. The TGC provides services for state-of-
the-art genome editing and to generate and maintain transgenic mice. These include: 1) the microinjection of
DNA constructs, CRISPR/Cas9, and lentiviral vectors into early mouse embryos, 2) microinjection of gene-
targeted mouse embryonic stem (ES) cells into blastocysts, 3) in-vitro fertilization , 4) embryo and sperm
cryopreservation, 5) re-derivation of mouse lines provided from non-standard sources, 6) gene targeting in
mouse ES cells, 7) targeting vector design and construction, 8) de novo derivation of ES cell lines, and 9) ES
cell expansion and preparation for microinjection. In addition, the TGC offers services for the injection of human
ES cell lines and induced pluripotent stem cell (iPSC) lines into immunodeficient mice to assess their ability to
form teratomas. The TGC develops new techniques and applications and provides immediate access to
individuals with prior knowledge of transgenic and knock out mouse models. For those lacking experience, the
TGC provides individual consultations, as well as group meetings, to discuss strategies for model development
and recent innovations in transgenic and gene targeting technologies that may be relevant to the researcher’s
goals. Overall, the transgenic and gene-targeting services provided by the TGC greatly increase the pace at
which mouse models can be generated, and at significantly lower cost, than commercial sources. All activities
of the TGC are overseen by the Institutional Animal Care and Use Committee (IACUC).

## Key facts

- **NIH application ID:** 10769675
- **Project number:** 2P30CA014195-51
- **Recipient organization:** SALK INSTITUTE FOR BIOLOGICAL STUDIES
- **Principal Investigator:** Geoffrey Myles Wahl
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $184,351
- **Award type:** 2
- **Project period:** 1996-12-31 → 2029-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10769675

## Citation

> US National Institutes of Health, RePORTER application 10769675, Transgenic Core (TGC) (2P30CA014195-51). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10769675. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*